As of 17 Sept 2026, Dr Agarwals Eye Hospital Ltd share price is ₹5,278.65. The stock opened at ₹5,278.65 and had closed at ₹5,136.40 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹4,412.05 and a high of ₹6,392.00. In terms of performance, Dr Agarwals Eye Hospital Ltd share price has increased by 10.52% over the past six months and has increased by 12.78% over the last year.
DRAGARWQ Stock Price Chart
Dr Agarwals Eye Hospital Ltd Overview
About DRAGARWQ
Dr Agarwals Eye Hospital is primarily engaged in running, owning and managing eye care hospitals, opticals, pharmacies, etc. and related services.
Dr Agarwals Eye Hospital Ltd Historical Performance
Dr Agarwals Eye Hospital Ltd Fundamentals
Dr Agarwals Eye Hospital Ltd Financials
| Indicator | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Revenue | 476.69 | 402.24 | 324.27 | 269.65 | 202.47 |
| EBITDA | 151.13 | 123.59 | 96.03 | 76.45 | 58.93 |
| Net Profit | 70.10 | 54.65 | 46.36 | 36.92 | 24.10 |
| EPS | 147.02 | 116.28 | 98.64 | 78.55 | 51.29 |
Dr Agarwals Eye Hospital Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 5,034.93 |
| Resistance 1 (R1) | 5,313.93 |
| Pivot Point | 5,212.47 |
Dr Agarwals Eye Hospital Ltd Dividend History
| Ex Date | Dividends Date | Record Date | Dividend Type | Dividend Details |
|---|---|---|---|---|
| 02-Sep-2026 | 20-May-2026 | 02-Sep-2026 | Final | ₹4.00 |
| 07-Nov-2025 | 30-Oct-2025 | 07-Nov-2025 | Interim | ₹3.00 |
| 18-Sep-2025 | 28-May-2025 | 18-Sep-2025 | Final | ₹3.50 |
| 08-Nov-2024 | 29-Oct-2024 | 08-Nov-2024 | Interim | ₹2.50 |
| 19-Aug-2024 | 25-Apr-2024 | 20-Aug-2024 | Final | ₹2.50 |
DRAGARWQ Key Leadership Details
Last Updated: Mar 2025
| Name | Position |
|---|---|
| Amar Agarwal. | Chairman & Managing Director |
| Athiya Agarwal | Whole-time Directorector |
| V Balakrishnan | Non Executive Independent Director |
Dr Agarwals Eye Hospital Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Apollo Hospitals Enterprise LtdAPOLLOHOSP | ₹8,696.50-0.20% | ₹1,10,231.07 | 59.08 | 20.48% |
| Max Healthcare Institute LtdMAXHEALTH | ₹1,025.00-0.49% | ₹1,02,534.79 | 72.27 | 13.42% |
| Fortis Healthcare LtdFORTIS | ₹870.30-1.11% | ₹68,746.49 | 70.10 | 10.53% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of Dr Agarwals Eye Hospital Ltd today is ₹5,278.65 on NSE and ₹5,278.65 on BSE.
- The 52-week high of Dr Agarwals Eye Hospital Ltd is ₹6,392.00, while the 52-week low is ₹4,412.05.
- The current market capitalisation of Dr Agarwals Eye Hospital Ltd is approximately ₹2,482 crore.
- The P/E (Price-to-Earnings) ratio of Dr Agarwals Eye Hospital Ltd is 33.47. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of Dr Agarwals Eye Hospital Ltd is 7.37. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy Dr Agarwals Eye Hospital Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for DRAGARWQ on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, Dr Agarwals Eye Hospital Ltd has delivered a return of approximately 120.79%. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of Dr Agarwals Eye Hospital Ltd comprises different categories of shareholders. As of Jun 2026, the shareholding is approximately 72.67% promoters, 2.21% FIIs, 2.05% DIIs, and 18.01% public shareholders.

